TScan TherapeuticsTCRX
About: TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Employees: 195
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
94% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 16
1% more funds holding
Funds holding: 89 [Q3] → 90 (+1) [Q4]
6% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 16
0% more funds holding in top 10
Funds holding in top 10: 5 [Q3] → 5 (+0) [Q4]
1.36% less ownership
Funds ownership: 85.97% [Q3] → 84.61% (-1.36%) [Q4]
39% less capital invested
Capital invested by funds: $209M [Q3] → $126M (-$82.2M) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Morgan Stanley Maxwell Skor 0% 1-year accuracy 0 / 3 met price target | 525%upside $10 | Overweight Assumed | 14 Mar 2025 |
Barclays Peter Lawson 10% 1-year accuracy 2 / 20 met price target | 88%upside $3 | Overweight Maintained | 7 Mar 2025 |
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 116 / 357 met price target | 838%upside $15 | Buy Reiterated | 6 Mar 2025 |
Needham Gil Blum 12% 1-year accuracy 19 / 159 met price target | 463%upside $9 | Buy Maintained | 5 Mar 2025 |
Financial journalist opinion
Based on 4 articles about TCRX published over the past 30 days









